🇺🇸 FDA

Intelligence · Patents

Expiring patents (≤24 months)

Patent cliff watchlist — pharmaceutical patents approaching loss of exclusivity.

Patents
1,230

Quick answer

1,230 pharmaceutical patents in our index expire within the next 24 months. Use year facets below for annual patent-cliff planning linked to company and drug profiles.

  1. US 7374931

    Vaccine against staphylococcus intoxication

    The United States of America as represented by the Secretary of the Army · Granted Tue May 20 2008 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 15 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 7375181

    Process for purifying glycopeptide phosphonate derivatives

    Theravance, Inc. · Granted Tue May 20 2008 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 15 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 7378403

    Akt inhibitors, pharmaceutical compositions, and uses thereof

    The United States of America, as represented by the Department of Health and Human Services · Granted Tue May 27 2008 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 22 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 7378386

    Anti-viral treatment methods using phosphatidylethanolamine-binding peptide derivatives

    The Board of Regents of the University of Texas System · Granted Tue May 27 2008 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 22 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 7378496

    hKCa3/KCNN3 small conductance calcium activated potassium channel: a diagnostic marker and therapeutic target

    The Regents of the University of California · Granted Tue May 27 2008 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 22 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 7378469

    Method for the preparation of 1-benzotriazolyl carbonate esters of poly(ethylene glycol)

    Nektar Therapeutics AL, Corporation · Granted Tue May 27 2008 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 22 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 7378093

    Broadly cross-reactive neutralizing antibodies against Human Immunodeficiency Virus selected by Env-CD4-co-receptor complexes

    The United States of America, as represented by the Department of Health and Human Services · Granted Tue May 27 2008 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 22 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 7378095

    Methods of treating type I diabetes by blocking VEGF-mediated activity

    REGENERON PHARMACEUTICALS, INC. · Granted Tue May 27 2008 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 22 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  9. US 7378552

    Monoamine re-uptake inhibitors and methods relating thereto

    Neurocrine Biosciences, Inc. · Granted Tue May 27 2008 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 22 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  10. US 7378251

    Methods of identifying compounds that modulate IL-4 receptor-mediated IgE synthesis utilizing a thioredoxin-like 32 kDa protein

    Rigel Pharmaceuticals, Inc. · Granted Tue May 27 2008 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 22 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  11. US 7378276

    Method of inducing memory B cell development and terminal differentiation

    The United States of America, as represented by the Department of Health and Human Services · Granted Tue May 27 2008 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 22 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  12. US 7378257

    Bacterial superantigen vaccines

    The United States of America as represented by the Secretary of the Army · Granted Tue May 27 2008 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 22 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  13. US 7378108

    Percutaneous absorption preparation of compound having angiotensin II antagonistic activity

    Takeda Pharmaceutical Company Limited · Granted Tue May 27 2008 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 22 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  14. US 7378273

    Expression vectors

    Gala Design, Inc. · Granted Tue May 27 2008 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 22 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  15. US 7378097

    Use of penetration enhancers and barrier disruption methods to enhance the immune response of antigen and adjuvant

    The United States of America as represented by the Secretary of the Army · Granted Tue May 27 2008 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 22 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  16. US 7378277

    Methods and compositions for transforming dendritic cells and activating T cells

    The United States of America, as represented by the Department of Health and Human Services · Granted Tue May 27 2008 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 22 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  17. US 7378553

    Isolated atomoxetine impurity, processes for the preparation of atomoxetine impurities and their use as reference standards

    Teva Pharmaceutical Fine Chemicals S.R.L. · Granted Tue May 27 2008 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 22 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  18. US 7378422

    Inhibitors of serine proteases, particularly HCV NS3-NS4A protease

    Vertex Pharmaceuticals Incorporated · Granted Tue May 27 2008 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 22 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  19. US 7381827

    Processes and intermediates

    Vertex Pharmaceuticals Incorporated · Granted Tue Jun 03 2008 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 29 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  20. US 7381405

    Methods of preparing lymphocytes that express interleukin-2 and their use in the treatment of cancer

    The United States of America, as represented by the Department of Health and Human Services · Granted Tue Jun 03 2008 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 29 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  21. US 7381408

    Methods for chemically synthesizing immunoglobulin chimeric proteins

    Syntonix Pharmaceuticals, Inc. · Granted Tue Jun 03 2008 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 29 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  22. US 7381404

    Treatment for dry macular degeneration

    The Regents of the University of California · Granted Tue Jun 03 2008 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 29 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  23. US 7381748

    Compounds and related methods for inhibition of gamma-aminobutyric acid aminotransferase

    Northwestern University · Granted Tue Jun 03 2008 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 29 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  24. US 7381825

    Histone deacetylase inhibitors

    Takeda San Diego, Inc. · Granted Tue Jun 03 2008 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 29 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  25. US 7381699

    Reagents and methods for smooth muscle therapies

    THE ARIZONA BOARD OF REGENTS · Granted Tue Jun 03 2008 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 29 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  26. US 7381744

    Method of treating osteoporosis comprising vacuolar-type (H+)-ATPase-inhibiting compounds

    The United States of America, as represented by the Department of Health and Human Services · Granted Tue Jun 03 2008 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 29 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  27. US 7384921

    Polymorphic forms of 6-11 bicyclic ketolide derivatives

    Enanta Pharmaceuticals, Inc. · Granted Tue Jun 10 2008 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 05 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  28. US 7384978

    Compounds and methods for delivery of prostacyclin analogs

    United Therapeutics Corporation · Granted Tue Jun 10 2008 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 05 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  29. US 7384909

    Anti-viral treatment methods using phosphatidylethanolamine-binding peptides linked to anti-viral agents

    The Board of Regents of the University of Texas System · Granted Tue Jun 10 2008 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 05 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  30. US 7384623

    High energy phototherapeutic agents

    Provectus Pharmatech, Inc. · Granted Tue Jun 10 2008 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 05 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

What is a patent cliff?

A patent cliff is when key pharmaceutical patents expire, opening markets to generics or biosimilars. This hub lists USPTO patents with approaching expiration dates.

Are expiration dates estimates?

Expiration dates derive from USPTO PatentsView grant dates and term estimates. Confirm with Orange Book, patent counsel, and USPTO records before investment decisions.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.